What is the management approach for a patient with a positive Antinuclear Antibody (ANA) result and a Dense Fine Speckled 70 (DSF70) pattern on immunofluorescence testing?

Management of Positive ANA with DSF70 Pattern

A positive ANA with an isolated DSF70 pattern (confirmed by specific anti-DFS70 antibody testing) effectively excludes systemic autoimmune rheumatic disease and requires no further autoimmune workup or rheumatology referral. 1, 2

Understanding the DSF70 Pattern

• The dense fine speckled 70 (DFS70) pattern represents antibodies against the DFS70/LEDGF-P75 antigen and is more commonly found in healthy individuals and non-autoimmune inflammatory conditions rather than systemic autoimmune rheumatic diseases (SARD). 1

• Anti-DFS70 antibodies serve as a negative biomarker for SARD, meaning their isolated presence argues against rather than for autoimmune disease. 2, 3

• The prevalence of anti-DFS70 in healthy blood donors ranges from 0.59-0.78%, while it can be found in various non-autoimmune inflammatory conditions. 4

Critical Confirmation Step Required

The DFS70 pattern observed on indirect immunofluorescence (IIF) must be confirmed with a specific anti-DFS70 antibody test (ELISA or chemiluminescence assay) before concluding the result is clinically insignificant. 5, 6

• Among sera showing a DFS70 pattern by IIF, only 30.4% are confirmed positive for anti-DFS70 antibodies by specific testing, meaning approximately 70% of apparent DFS70 patterns on IIF are false positives. 5

• Without confirmation testing, you risk missing true SARD-associated autoantibodies that may produce a similar-appearing pattern on IIF. 5, 6

• The HEp-2 Select immunoadsorption method can eliminate DFS70 interference in 95.7% of cases, revealing other autoantibody patterns that may be clinically significant. 5

Management Algorithm

If Anti-DFS70 is Confirmed Positive by Specific Testing:

• Check for concomitant SARD-specific autoantibodies (anti-dsDNA, anti-ENA panel including anti-Sm, anti-RNP, anti-SSA/Ro, anti-SSB/La, anti-Scl-70, anti-Jo-1). 1, 6

• If anti-DFS70 is isolated (no other SARD-specific antibodies present):

  • No further autoimmune workup is needed 2, 3
  • No rheumatology referral is required 3
  • Reassure the patient that this does not indicate autoimmune disease 2
  • Address the underlying clinical symptoms with appropriate non-rheumatologic evaluation 2

• If anti-DFS70 is present WITH other SARD-specific autoantibodies:

  • The presence of anti-DFS70 becomes clinically irrelevant 6
  • Manage based on the SARD-specific autoantibodies and clinical presentation 1, 6
  • Proceed with appropriate rheumatology referral if indicated by titer (≥1:160) and clinical symptoms 1

If DFS70 Pattern on IIF is NOT Confirmed by Specific Testing:

• The IIF result represents a false positive DFS70 pattern 5
• Proceed with standard ANA workup based on the actual titer and any alternative patterns identified 1, 7
• Order specific ENA panel and anti-dsDNA testing as clinically indicated 1, 7

Clinical Significance and Cost-Effectiveness

• In a 10-year follow-up study, none of the 181 patients with isolated anti-DFS70 antibodies developed SARD, confirming its negative predictive value. 3

• Implementing anti-DFS70 testing in the diagnostic algorithm reduces unnecessary follow-up testing by approximately 70% and is highly cost-effective, saving over €60,000 in a pilot study through avoided ENA testing, anti-dsDNA testing, and outpatient visits. 3

• Anti-DFS70 antibodies may be found in 7.5% of patients with established SARD, but virtually always in conjunction with other SARD-specific autoantibodies. 4

Common Pitfalls to Avoid

• Never rely on IIF pattern alone: The DFS70 pattern has a 70% false positive rate on IIF and must be confirmed with specific anti-DFS70 antibody testing. 5

• Do not skip testing for SARD-specific autoantibodies: Even when anti-DFS70 is confirmed, you must verify the absence of concomitant SARD-specific antibodies, as 11.5% of DFS70-positive cases may have clinically significant autoantibodies. 6

• Avoid unnecessary monitoring: Patients with isolated anti-DFS70 do not require serial ANA testing or rheumatology follow-up. 3

• Consider the clinical context: Anti-DFS70 antibodies can be found in various inflammatory conditions (such as the acute glomerulonephritis case described), and their presence helps exclude autoimmune etiology for the presenting symptoms. 2